Browse our 650+ Publications​

Latest Publications

Diagnosis and Tracking of SARS-CoV-2 Infection By T-Cell Receptor Sequencing

Gittelman RM., et al.
February 2021
Authors and Affiliates
Rachel M. Gittelman 1, Enrico Lavezzo 2, Thomas M. Snyder 1, H. Jabran Zahid 3, Rebecca Elyanow 1, Sudeb Dalai 1,4, Ilan Kirsch 1, Lance Baldo 1, Laura Manuto 2, Elisa Franchin 2, Claudia Del Vecchio 2, Monia Pacenti 5, Caterina Boldrin 5, Margherita Cattai 5, Francesca Saluzzo 2, Andrea Padoan 6, Mario Plebani 6, Fabio Simeoni 7, Jessica Bordini 8, Nicola I. Lorè 9, Dejan Lazarevic 7, Daniela M. Cirillo 9, Paolo Ghia 8,10, Stefano Toppo 2,11, Jonathan M. Carlson 3, Harlan S. Robins 1, Giovanni Tonon 7,8, Andrea Crisanti 2,12; 1 Adaptive Biotechnologies, Seattle, WA, USA 2 Department of Molecular Medicine, University of Padova, Padua, Italy 3 Microsoft Research, Redmond, WA, USA 4 Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine 5 Azienda Ospedale Padova, Microbiology and Virology Unit, Padua, Italy 6 Department of Medicine, University of Padova, Padua, Italy 7 Center for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy 8 Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy 9 Division of Immunology, Transplantation and Infectious Disease, IRCCS Ospedale San Raffaele, Milan, Italy 10 Università Vita- Salute San Raffaele, Milan, Italy 11 CRIBI Biotech Center, University of Padova, Padua, Italy 12 Department of Life Sciences, Imperial College London, London, UK

Safety, anti-tumor activity and T-cell responses in a dose-ranging phase 1 trial of the oncolytic peptide LTX-315 in patients with solid tumors

Spicer J., et al.
Clinical Cancer Research
February 2021
Authors and Affiliates
James Spicer 1, Aurelien Marabelle 2, Jean-Francois Baurain 3, Nina Louise Jebsen 4, Dag Eirik Jøssang 5, Ahmad Awada 6, Rebecca Kristeleit 7, Delphine Loirat 8, George Lazaridis 9, Christiane Jungels 10, Paal Brunsvig 11, Berit Nicolaisen 12, Andrew Saunders 13, Hamina Patel 13, Jerome Galon 14, Fabienne Hermitte 15, Ketil André Camilio 13, Brynjar Mauseth 13, Vibeke Sundvold 16, Baldur Sveinbjørnsson 17, Øystein Rekdal 13; 1 School Cancer & Pharmacological Sciences, King's College London james.spicer@kcl.ac.uk. 2 Institut Gustave Roussy. 3 King Albert II Cancer Institute, Cliniques Universitaires Saint-Luc. 4 Centre for Cancer Biomarkers, Dep. of Clinical Science and Dep. of Oncology, University of Bergen and Haukeland University Hospital, Bergen. 5 Haukeland University Hospital. 6 Oncology Medicine Department, Institut Jules Bordet, Université Libre de Bruxelles. 7 Dept of Oncology, Guy's and St Thomas' NHS Foundation Trust. 8 Medical Oncology, Institute Curie. 9 Guy's Hospital, King's College London. 10 Department of Medical Oncology, Institut Jules Bordet. 11 Oslo University Hospital. 12 Medical, Lytix Biopharma AS. 13 Lytix Biopharma AS. 14 Inserm U1138, Laboratory of Integrative Cancer Immunology. 15 Medical Affairs, HalioDx, Marseille, France. 16 Biopharma, Lytix Biopharma (Norway). 17 Cell Biology and Histology, University of Norway.

A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

Nowicki NS., et a.
Clinical Cancer Research
February 2021
Authors and Affiliates
Theodore S Nowicki 1, Beata Berent-Maoz 2, Gardenia Cheung-Lau 2, Rong Rong Huang 3, Xiaoyan Wang 4, Jennifer Tsoi 2, Paula Kaplan-Lefko 2, Paula Cabrera 2, Justin Tran 2, Jia Pang 2, Mignonette Macabali 2, Ivan Perez Garcilazo 2, Ignacio Baselga Carretero 2, Anusha Kalbasi 5,6,7, Alistair J Cochran 3, Catherine S Grasso 2, Siwen Hu-Lieskovan 2, Bartosz Chmielowski 2, Begoña Comin-Anduix 6,7, Arun Singh 8, Antoni Ribas 8,6,7,9,10; 1 Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California. 2 Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California. 3 Department of Pathology, University of California Los Angeles, Los Angeles, California. 4 Department of General Internal Medicine and Health Services Research, University of California Los Angeles, Los Angeles, California. 5 Division of Molecular and Cellular Oncology, Department of Radiation Oncology, University of California Los Angeles, Los Angeles, California. 6 Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California. 7 Division of Surgical-Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California. 8 Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California. asingh@mednet.ucla.edu aribas@mednet.ucla.edu. 9 Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California Los Angeles, Los Angeles, California. 10 Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California.

CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients

Amini L., et al.
Molecular Therapy
February 2021
Authors and Affiliates
Leila Amini 1, Dimitrios Laurin Wagner 2, Uta Rössler 3, Ghazaleh Zarrinrad 4, Livia Felicitas Wagner 5, Tino Vollmer 6, Désirée Jacqueline Wendering 7, Uwe Kornak 3, Hans-Dieter Volk 1, Petra Reinke 2, Michael Schmueck-Henneresse 8; 1 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. 2 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. 3 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Institute of Medical Genetics and Human Genetics, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. 4 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Einstein Center for Regenerative Therapies, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. 5 Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. 6 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. 7 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. 8 Berlin Institute of Health (BIH) Center for Regenerative Therapies (B-CRT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany; Berlin Center for Advanced Therapies (BeCAT), Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany. Electronic address: michael.schmueck-henneresse@charite.de.

Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors

Crosby EJ., et al.
OncoImmunology
February 2021
Authors and Affiliates
Erika J Crosby 1, Junping Wei 1, Xiao Yi Yang 1, Gangjun Lei 1, Tao Wang 1, Cong-Xiao Liu 1, Pankaj Agarwal 1, Alan J Korman 2, Michael A Morse 1,3, Kenneth Gouin 4, Simon R V Knott 4, H Kim Lyerly 1,5, Zachary C Hartman 1; 1 Department of Surgery, Duke University, Durham, NC, United States. 2 Immuno-Oncology Discovery, Bristol-Myers Squibb Company, Redwood City, CA, United States. 3 Department of Medicine, Duke University, Durham, NC, United States. 4 Department of Biomedical Sciences, Cedars-Sinai Medical Institute, Los Angeles, CA, United States. 5 Department of Pathology/Immunology, Duke University, Durham, NC, United States

Characterization of human T cell receptor repertoire data in eight thymus samples and four related blood samples

Heikkilä N., et al.
Data in Brief
January 2021
Authors and Affiliates
Nelli Heikkilä 1,2, Iivari Kleino 1, Reetta Vanhanen 1,2, Dawit A. Yohannes 1,3, Ilkka P. Mattila 4, Jari Saramäki 5, T. Petteri Arstila 1,2; 1 Research Programs Unit, Translational Immunology, University of Helsinki, Haartmaninkatu 3, 00290 Helsinki, Finland 2 Medicum, Department of Bacteriology and Immunology, University of Helsinki, Haartmaninkatu 3, 00290 Helsinki, Finland 3 Department of Medical and Clinical Genetics, University of Helsinki, Haartmaninkatu 8, 00290 Helsinki 4 Department of Pediatric Cardiac and Transplantation Surgery, Hospital for Children and Adolescents, Helsinki University Central Hospital, Stenbäckinkatu 9, 00290 Helsinki, Finland 5 Department of Computer Science, Aalto University, Konemiehentie 2, 02150 Espoo, Finland

CDR3 and V genes show distinct reconstitution patterns in T cell repertoire post-allogeneic bone marrow transplantation

Tickotsky-Moskovitz N., et al.
Immunogenetics
January 2021
Authors and Affiliates
Nili Tickotsky-Moskovitz 1, Yoram Louzoun 2, Shirit Dvorkin 3, Adi Rotkopf 4, Amir Asher Kuperman 4,5, Sol Efroni 1; 1 The Goodman Faculty of Life Sciences, Bar Ilan University, Ramat Gan, Israel. 2 Department of Mathematics, Bar Ilan University, Ramat Gan, Israel. louzouy@math.biu.ac.il. 3 Department of Mathematics, Bar Ilan University, Ramat Gan, Israel. 4 Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel. 5 Blood Coagulation Service and Pediatric Hematology Clinic, Galilee Medical Center, Nahariya, Israel.

Characterization of ascites- and tumor-infiltrating γδ T cells reveals distinct repertoires and a beneficial role in ovarian cancer

Foord E., et al.
Science Translational Medicine
January 2021
Authors and Affiliates
Emelie Foord 1, Lucas C M Arruda 2, Ahmed Gaballa 2,3, Charlotte Klynning 4, Michael Uhlin 2,5,6; 1 Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 171 77 Stockholm, Sweden. emelie.foord@ki.se. 2 Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 171 77 Stockholm, Sweden. 3 Department of Clinical Biochemistry, National Liver Institute, Menoufia University, 511 32 Shebin Elkom, Egypt. 4 Department of Gynecological Oncology, Karolinska University Hospital, 171 76 Stockholm, Sweden. 5 Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, 141 86 Stockholm, Sweden. 6 Department of Applied Physics, Royal Institute of Technology, 100 44 Stockholm, Sweden.

The TCR repertoire of α-synuclein-specific T cells in Parkinson’s disease is surprisingly diverse

Singhania A., et al.
Scientific Reports
January 2021
Authors and Affiliates
Akul Singhania 1, John Pham 1, Rekha Dhanwani 1, April Frazier 1, Juliana Rezende Dutra 2, Karen S Marder 2, Elizabeth Phillips 3,4, Simon Mallal 3,4, Amy W Amara 5, David G Standaert 5, David Sulzer 2,6,7, Bjoern Peters 1,8, Alessandro Sette 1,8, Cecilia S Lindestam Arlehamn 9; 1 Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA. 2 Department of Neurology, Columbia University Medical Center, New York, NY, 10032, USA. 3 Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA, 6150, Australia. 4 Vanderbilt University School of Medicine, Nashville, TN, 37235, USA. 5 Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, 35233, USA. 6 Department of Psychiatry, Columbia University Medical Center, New York, NY, 10032, USA. 7 Department of Pharmacology, Columbia University Medical Center, New York, NY, 10032, USA. 8 Department of Medicine, University of California San Diego, La Jolla, CA, 92093, USA. 9 Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA. cecilia@lji.org.

Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups

Lee S., et al.
iScience
January 2021
Authors and Affiliates
Sanghoon Lee 1, Li Zhao 2, Latasha D. Little 2, Shannon N. Westin 3, Amir A. Jazarei 3, Nicole D. Fleming 3, Jianhua Zhang 2, P. Andrew Futreal 2, Anil K. Sood 3; 1 Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 3 Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA